Erratum: Corrigendum to “Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease” (Dig. Liver Dis. (2016) 48(4) (360–370))

Alessandro Armuzzi, Paolo Gionchetti, Marco Daperno, Silvio Danese, Ambrogio Orlando, Maria Lia Scribano, Maurizio Vecchi, Fernando Rizzello, Sandro Ardizzone, Alessandro Armuzzi, Fabiana Castiglione, Silvio Danese, Marco Daperno, Massimo Fantini, Gionata Fiorino, Giuseppe Frieri, Paolo Gionchetti, Luca Neri, Ambrogio Orlando, Mariabeatrice PrincipiFernando Rizzello, Maria Lia Scribano, Giacomo Carlo Sturniolo, Maurizio Vecchi, GIVI (Gruppo Italiano su Vedolizumab nelle IBD) Group

Research output: Contribution to journalComment/debate

Abstract

In the last paragraph of Section 1, the sentence “VDZ is a monoclonal antibody blocking the α4β7 integrin which is selectively expressed by the vascular endothelium in the gastrointestinal tract [7]” should be replaced with: “VDZ is a monoclonal antibody blocking the α4β7 integrin which is selectively expressed by the activated GUT homing lymphocytes [7]”. Mariabeatrice Principi, Gastroenterology Section, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy, should have been listed in Appendix A (Members of the GIVI Study Group).

Original languageEnglish
Pages (from-to)1103
Number of pages1
JournalDigestive and Liver Disease
Volume48
Issue number9
DOIs
Publication statusPublished - Sep 1 2016

ASJC Scopus subject areas

  • Medicine(all)
  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Erratum: Corrigendum to “Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease” (Dig. Liver Dis. (2016) 48(4) (360–370))'. Together they form a unique fingerprint.

  • Cite this

    Armuzzi, A., Gionchetti, P., Daperno, M., Danese, S., Orlando, A., Scribano, M. L., Vecchi, M., Rizzello, F., Ardizzone, S., Armuzzi, A., Castiglione, F., Danese, S., Daperno, M., Fantini, M., Fiorino, G., Frieri, G., Gionchetti, P., Neri, L., Orlando, A., ... GIVI (Gruppo Italiano su Vedolizumab nelle IBD) Group (2016). Erratum: Corrigendum to “Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease” (Dig. Liver Dis. (2016) 48(4) (360–370)). Digestive and Liver Disease, 48(9), 1103. https://doi.org/10.1016/j.dld.2016.06.015